PNC Financial Services Group’s ArriVent BioPharma AVBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$9.9K Buy
328
+114
+53% +$3.49K ﹤0.01% 4186
2026
Q2
$7.43K Sell
214
-112
-34% -$3.31K ﹤0.01% 4228
2026
Q1
$7.52K Buy
326
+189
+138% +$4.27K ﹤0.01% 4076
2025
Q4
$2.76K Buy
137
+129
+1,613% +$2.68K ﹤0.01% 4446
2025
Q3
$148 Buy
+8
New +$157 ﹤0.01% 4965

Other funds holding AVBP

PNC Financial Services Group's AVBP Position: Q3 2026 in Review

PNC Financial Services Group increased its ArriVent BioPharma (AVBP) stake by 53% in Q3 2026, buying an estimated $3.49K and bringing the position to 328 shares worth $9.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4186.

PNC Financial Services Group first reported a position in AVBP in Q3 2025 and has held it in 5 quarters since. 151 funds tracked by Wall St. Rank hold AVBP as of Q3 2026.

  • PNC Financial Services Group held 328 shares of ArriVent BioPharma worth $9.9K as of Q3 2026.
  • PNC Financial Services Group bought 114 ArriVent BioPharma shares in Q3 2026, an estimated $3.49K.
  • ArriVent BioPharma made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #4186 holding.
  • PNC Financial Services Group first reported a position in ArriVent BioPharma in Q3 2025 and has held it in 5 quarters since.
  • 151 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.